Hangzhou Biotest Biotech Co., Ltd. Class A

As of June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A carries a market capitalization of 4.85B, placing it among publicly traded companies globally. Its enterprise value stands at 3.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hangzhou Biotest Biotech Co., Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A has 149.33M shares outstanding.

As of June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 338.05. The price-to-sales ratio is 10.15, and the price-to-book ratio stands at 2.27.

As of June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A trades at an EV/EBITDA multiple of 522.13 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 522.13 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.69B versus a market cap of 4.85B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A maintains a current ratio of 9.51, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A posted a return on equity (ROE) of 0.62, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.57, measuring how efficiently the asset base is converted into earnings. The company generates approximately 769,893.52 in revenue per employee across its workforce of 610.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.46 indicates how many times Hangzhou Biotest Biotech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A recorded an income tax benefit of -6.33M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 6.41M, leaving 14.11M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A's stock has declined approximately 11.83% over the past 52 weeks. The 50-day moving average sits at 39.14, while the 200-day moving average is 37.74.

Over the twelve months ended June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A generated 470.02M in revenue and converted that into 14.11M in net income, yielding earnings per share of 0.09. EBITDA reached 7.07M, while operating income came in at 32.71M.

As of June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A holds 1.26B in cash and equivalents against 100.18M in total debt, resulting in a net debt position of -1.15B. Total book value stands at 2.14B, with working capital of 1.29B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A posted a gross margin of 46.67, reflecting its pricing power and cost economics. The operating margin of 6.96 and net profit margin of 3.00 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A paid dividends of 0.73 per share. The dividend payout ratio of 938.95 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.49, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hangzhou Biotest Biotech Co., Ltd. Class A shareholders.

Hangzhou Biotest Biotech Co., Ltd. Class A's most recent stock split took place on June 6, 2025 with a 5:7 split ratio.

As of June 30, 2026, Hangzhou Biotest Biotech Co., Ltd. Class A has an Altman Z-Score of 13.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.